AU2012307020B2 - Means for controlled sealing of endovascular devices - Google Patents

Means for controlled sealing of endovascular devices Download PDF

Info

Publication number: AU2012307020B2
Authority: AU; Australia
Prior art keywords: seal; endoluminal; prosthesis; implant; expandable
Prior art date: 2011-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2012307020A

Other languages

English (en)

Other versions

AU2012307020A1 (en

Inventor

Ben Colin Bobillier

Ashish Sudhir Mitra

Martin Kean Chong NG

Jens Sommer-Knudsen

Pak Man Victor Wong

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Endoluminal Sciences Pty Ltd

Original Assignee

Endoluminal Sciences Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-09

Filing date

2012-09-10

Publication date

2015-04-30

2012-05-21 Priority claimed from US13/476,695 external-priority patent/US9216076B2/en

2012-08-28 Priority claimed from US13/596,894 external-priority patent/US20130190857A1/en

2012-09-10 Application filed by Endoluminal Sciences Pty Ltd filed Critical Endoluminal Sciences Pty Ltd

2014-03-13 Publication of AU2012307020A1 publication Critical patent/AU2012307020A1/en

2015-04-30 Application granted granted Critical

2015-04-30 Publication of AU2012307020B2 publication Critical patent/AU2012307020B2/en

2015-07-27 Priority to AU2015205978A priority Critical patent/AU2015205978B2/en

Status Ceased legal-status Critical Current

2032-09-10 Anticipated expiration legal-status Critical

Links

238000007789 sealing Methods 0.000 title claims abstract description 75
239000000463 material Substances 0.000 claims abstract description 134
230000004913 activation Effects 0.000 claims abstract description 53
239000000017 hydrogel Substances 0.000 claims description 101
239000007943 implant Substances 0.000 claims description 72
239000012528 membrane Substances 0.000 claims description 71
-1 poly(methacrylic acids) Polymers 0.000 claims description 69
238000000034 method Methods 0.000 claims description 67
229920000642 polymer Polymers 0.000 claims description 61
239000012530 fluid Substances 0.000 claims description 33
239000006260 foam Substances 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 26
239000011148 porous material Substances 0.000 claims description 25
238000002513 implantation Methods 0.000 claims description 23
239000000853 adhesive Substances 0.000 claims description 19
230000001070 adhesive effect Effects 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 16
229920002627 poly(phosphazenes) Polymers 0.000 claims description 11
239000004088 foaming agent Substances 0.000 claims description 10
229910052751 metal Inorganic materials 0.000 claims description 9
239000002184 metal Substances 0.000 claims description 9
229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
150000004676 glycans Chemical class 0.000 claims description 8
229920001282 polysaccharide Polymers 0.000 claims description 8
239000005017 polysaccharide Substances 0.000 claims description 8
239000000758 substrate Substances 0.000 claims description 8
239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
229920001577 copolymer Polymers 0.000 claims description 7
239000003431 cross linking reagent Substances 0.000 claims description 7
239000007921 spray Substances 0.000 claims description 7
229920002125 Sokalan® Polymers 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
229920002689 polyvinyl acetate Polymers 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
229920001477 hydrophilic polymer Polymers 0.000 claims description 5
229920002126 Acrylic acid copolymer Polymers 0.000 claims description 4
239000000032 diagnostic agent Substances 0.000 claims description 4
229940039227 diagnostic agent Drugs 0.000 claims description 4
238000003475 lamination Methods 0.000 claims description 4
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 4
239000011118 polyvinyl acetate Substances 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
238000005336 cracking Methods 0.000 claims description 3
238000000151 deposition Methods 0.000 claims description 3
230000008021 deposition Effects 0.000 claims description 3
238000001125 extrusion Methods 0.000 claims description 3
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
230000000069 prophylactic effect Effects 0.000 claims description 3
238000001771 vacuum deposition Methods 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
230000000295 complement effect Effects 0.000 claims description 2
230000036961 partial effect Effects 0.000 claims description 2
230000000149 penetrating effect Effects 0.000 claims description 2
229940124597 therapeutic agent Drugs 0.000 claims description 2
238000009834 vaporization Methods 0.000 claims description 2
230000008016 vaporization Effects 0.000 claims description 2
239000011888 foil Substances 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
230000007246 mechanism Effects 0.000 abstract description 14
230000008901 benefit Effects 0.000 abstract description 13
239000002775 capsule Substances 0.000 description 98
239000003795 chemical substances by application Substances 0.000 description 80
239000000499 gel Substances 0.000 description 66
230000008961 swelling Effects 0.000 description 53
239000004971 Cross linker Substances 0.000 description 32
239000000243 solution Substances 0.000 description 25
230000008569 process Effects 0.000 description 22
229920001223 polyethylene glycol Polymers 0.000 description 21
229920002674 hyaluronan Polymers 0.000 description 17
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 16
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 16
210000001765 aortic valve Anatomy 0.000 description 15
229940099552 hyaluronan Drugs 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
239000000178 monomer Substances 0.000 description 15
206010002329 Aneurysm Diseases 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
229940079593 drug Drugs 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
125000005647 linker group Chemical group 0.000 description 13
229920001661 Chitosan Polymers 0.000 description 12
201000002064 aortic valve insufficiency Diseases 0.000 description 12
125000000524 functional group Chemical group 0.000 description 12
210000002216 heart Anatomy 0.000 description 12
239000010410 layer Substances 0.000 description 12
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 11
229920000615 alginic acid Polymers 0.000 description 11
235000010443 alginic acid Nutrition 0.000 description 11
238000002788 crimping Methods 0.000 description 11
239000007789 gas Substances 0.000 description 11
239000002245 particle Substances 0.000 description 11
206010002915 Aortic valve incompetence Diseases 0.000 description 10
229940072056 alginate Drugs 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
230000015556 catabolic process Effects 0.000 description 10
238000006731 degradation reaction Methods 0.000 description 10
238000011068 loading method Methods 0.000 description 10
238000003860 storage Methods 0.000 description 10
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000002260 anti-inflammatory agent Substances 0.000 description 9
238000005538 encapsulation Methods 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
238000011065 in-situ storage Methods 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000000576 coating method Methods 0.000 description 8
238000004132 cross linking Methods 0.000 description 8
229920001343 polytetrafluoroethylene Polymers 0.000 description 8
230000002792 vascular Effects 0.000 description 8
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
229920002554 vinyl polymer Polymers 0.000 description 8
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 7
239000004696 Poly ether ether ketone Substances 0.000 description 7
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 7
229910001870 ammonium persulfate Inorganic materials 0.000 description 7
229940121363 anti-inflammatory agent Drugs 0.000 description 7
206010002906 aortic stenosis Diseases 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
239000003999 initiator Substances 0.000 description 7
230000007774 longterm Effects 0.000 description 7
229920002530 polyetherether ketone Polymers 0.000 description 7
229920001296 polysiloxane Polymers 0.000 description 7
235000019422 polyvinyl alcohol Nutrition 0.000 description 7
239000002904 solvent Substances 0.000 description 7
125000006850 spacer group Chemical group 0.000 description 7
239000000126 substance Substances 0.000 description 7
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229920001287 Chondroitin sulfate Polymers 0.000 description 6
208000032750 Device leakage Diseases 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 6
239000004743 Polypropylene Substances 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 6
230000002308 calcification Effects 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
229940059329 chondroitin sulfate Drugs 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
125000004386 diacrylate group Chemical group 0.000 description 6
238000011049 filling Methods 0.000 description 6
239000010408 film Substances 0.000 description 6
210000003709 heart valve Anatomy 0.000 description 6
230000007062 hydrolysis Effects 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
229920001155 polypropylene Polymers 0.000 description 6
239000004810 polytetrafluoroethylene Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 5
108010035532 Collagen Proteins 0.000 description 5
102000008186 Collagen Human genes 0.000 description 5
208000001750 Endoleak Diseases 0.000 description 5
206010019280 Heart failures Diseases 0.000 description 5
206010027727 Mitral valve incompetence Diseases 0.000 description 5
206010067171 Regurgitation Diseases 0.000 description 5
125000000746 allylic group Chemical group 0.000 description 5
238000004873 anchoring Methods 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000004087 circulation Effects 0.000 description 5
229920001436 collagen Polymers 0.000 description 5
229940124447 delivery agent Drugs 0.000 description 5
238000001476 gene delivery Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229920006254 polymer film Polymers 0.000 description 5
238000006116 polymerization reaction Methods 0.000 description 5
229940068984 polyvinyl alcohol Drugs 0.000 description 5
238000001694 spray drying Methods 0.000 description 5
210000005166 vasculature Anatomy 0.000 description 5
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 4
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
208000036829 Device dislocation Diseases 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
108010039918 Polylysine Proteins 0.000 description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
210000003484 anatomy Anatomy 0.000 description 4
239000003011 anion exchange membrane Substances 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000034994 death Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000003292 glue Substances 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
210000004115 mitral valve Anatomy 0.000 description 4
229910001000 nickel titanium Inorganic materials 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
229920000656 polylysine Polymers 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000003566 sealing material Substances 0.000 description 4
239000012781 shape memory material Substances 0.000 description 4
229960002930 sirolimus Drugs 0.000 description 4
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
238000003466 welding Methods 0.000 description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000006399 behavior Effects 0.000 description 3
239000000560 biocompatible material Substances 0.000 description 3
229910052793 cadmium Inorganic materials 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000002843 carboxylic acid group Chemical group 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002131 composite material Substances 0.000 description 3
239000010949 copper Substances 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229920001971 elastomer Polymers 0.000 description 3
230000010102 embolization Effects 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
238000010363 gene targeting Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
125000001841 imino group Chemical group [H]N=* 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000010874 in vitro model Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
210000005240 left ventricle Anatomy 0.000 description 3
229920005615 natural polymer Polymers 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
230000002028 premature Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000010526 radical polymerization reaction Methods 0.000 description 3
230000008439 repair process Effects 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
230000008467 tissue growth Effects 0.000 description 3
239000010936 titanium Substances 0.000 description 3
229910052719 titanium Inorganic materials 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010006580 Bundle branch block left Diseases 0.000 description 2
206010006578 Bundle-Branch Block Diseases 0.000 description 2
108091068251 CCN family Proteins 0.000 description 2
102000039854 CCN family Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010009685 Cholinergic Receptors Proteins 0.000 description 2
229920001651 Cyanoacrylate Polymers 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
229920000926 Galactomannan Polymers 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
229920000877 Melamine resin Polymers 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
239000004697 Polyetherimide Substances 0.000 description 2
239000004642 Polyimide Substances 0.000 description 2
239000004721 Polyphenylene oxide Substances 0.000 description 2
229920002323 Silicone foam Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010064396 Stent-graft endoleak Diseases 0.000 description 2
102000007000 Tenascin Human genes 0.000 description 2
108010008125 Tenascin Proteins 0.000 description 2
229920002807 Thiomer Polymers 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
150000001241 acetals Chemical class 0.000 description 2
102000034337 acetylcholine receptors Human genes 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
229910045601 alloy Inorganic materials 0.000 description 2
239000000956 alloy Substances 0.000 description 2
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 2
239000003098 androgen Substances 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
230000000712 assembly Effects 0.000 description 2
238000000429 assembly Methods 0.000 description 2
210000001008 atrial appendage Anatomy 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
229960000397 bevacizumab Drugs 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
238000000071 blow moulding Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000011128 cardiac conduction Effects 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
229920006317 cationic polymer Polymers 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
229960000640 dactinomycin Drugs 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
239000000412 dendrimer Substances 0.000 description 2
229920000736 dendritic polymer Polymers 0.000 description 2
238000013461 design Methods 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000013013 elastic material Substances 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
238000005187 foaming Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
229910052733 gallium Inorganic materials 0.000 description 2
239000007863 gel particle Substances 0.000 description 2
229960000578 gemtuzumab Drugs 0.000 description 2
230000012010 growth Effects 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
239000000416 hydrocolloid Substances 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
201000001715 left bundle branch hemiblock Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
108700005457 microfibrillar Proteins 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229920009441 perflouroethylene propylene Polymers 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
125000004437 phosphorous atom Chemical group 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920000570 polyether Polymers 0.000 description 2
229920001601 polyetherimide Polymers 0.000 description 2
229920001721 polyimide Polymers 0.000 description 2
239000002861 polymer material Substances 0.000 description 2
230000000379 polymerizing effect Effects 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000004321 preservation Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
229960003912 probucol Drugs 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000000565 sealant Substances 0.000 description 2
239000013514 silicone foam Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
238000011301 standard therapy Methods 0.000 description 2
125000000542 sulfonic acid group Chemical group 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
239000010409 thin film Substances 0.000 description 2
229910052718 tin Inorganic materials 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
238000007666 vacuum forming Methods 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 2
229950009819 zotarolimus Drugs 0.000 description 2
BISKEOIROPAOGY-RXQQAGQTSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2r)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@@H](NC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C=O)C1=CC=CC=C1 BISKEOIROPAOGY-RXQQAGQTSA-N 0.000 description 1
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 1
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
KWIPUXXIFQQMKN-UHFFFAOYSA-N 2-azaniumyl-3-(4-cyanophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-UHFFFAOYSA-N 0.000 description 1
JCBWQNLTYXTHBZ-UHFFFAOYSA-N 2-azidobenzoic acid Chemical group OC(=O)C1=CC=CC=C1N=[N+]=[N-] JCBWQNLTYXTHBZ-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010004552 Bicuspid aortic valve Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
101150042405 CCN1 gene Proteins 0.000 description 1
101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229910017518 Cu Zn Inorganic materials 0.000 description 1
229910017535 Cu-Al-Ni Inorganic materials 0.000 description 1
229910017755 Cu-Sn Inorganic materials 0.000 description 1
229910017752 Cu-Zn Inorganic materials 0.000 description 1
229910017927 Cu—Sn Inorganic materials 0.000 description 1
229910017943 Cu—Zn Inorganic materials 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108091027757 Deoxyribozyme Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
229920001780 ECTFE Polymers 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical class CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
229940124761 MMP inhibitor Drugs 0.000 description 1
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
238000006845 Michael addition reaction Methods 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000020128 Mitral stenosis Diseases 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
229910001257 Nb alloy Inorganic materials 0.000 description 1
229910003310 Ni-Al Inorganic materials 0.000 description 1
208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229920001774 Perfluoroether Polymers 0.000 description 1
102000003666 Placenta Growth Factor Human genes 0.000 description 1
108010082093 Placenta Growth Factor Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
229910001260 Pt alloy Inorganic materials 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
229910001362 Ta alloys Inorganic materials 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
108010039185 Tenecteplase Proteins 0.000 description 1
201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 1
229910001069 Ti alloy Inorganic materials 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
229910010977 Ti—Pd Inorganic materials 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
LGYAJKZELZXFKL-UHFFFAOYSA-N [Mn].[Cr].[Si].[Mn].[Fe] Chemical compound [Mn].[Cr].[Si].[Mn].[Fe] LGYAJKZELZXFKL-UHFFFAOYSA-N 0.000 description 1
IWTGVMOPIDDPGF-UHFFFAOYSA-N [Mn][Si][Fe] Chemical compound [Mn][Si][Fe] IWTGVMOPIDDPGF-UHFFFAOYSA-N 0.000 description 1
GMVPEJUTFFCKDK-UHFFFAOYSA-N [Nb].[U] Chemical compound [Nb].[U] GMVPEJUTFFCKDK-UHFFFAOYSA-N 0.000 description 1
WCERXPKXJMFQNQ-UHFFFAOYSA-N [Ti].[Ni].[Cu] Chemical compound [Ti].[Ni].[Cu] WCERXPKXJMFQNQ-UHFFFAOYSA-N 0.000 description 1
ZETVWNYVYYVTAU-UHFFFAOYSA-N [Ti].[Ni].[Hf] Chemical compound [Ti].[Ni].[Hf] ZETVWNYVYYVTAU-UHFFFAOYSA-N 0.000 description 1
CTHCNINEXYPGQP-UHFFFAOYSA-N [Zn].[Cu].[Zr] Chemical compound [Zn].[Cu].[Zr] CTHCNINEXYPGQP-UHFFFAOYSA-N 0.000 description 1
208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940090948 ammonium benzoate Drugs 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002095 anti-migrative effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
229960003856 argatroban Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229960004669 basiliximab Drugs 0.000 description 1
XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
229950001858 batimastat Drugs 0.000 description 1
229960002938 bexarotene Drugs 0.000 description 1
208000021654 bicuspid aortic valve disease Diseases 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000005312 bioglass Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
238000007664 blowing Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
229930006711 bornane-2,3-dione Natural products 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
WJCRZORJJRCRAW-UHFFFAOYSA-N cadmium gold Chemical compound [Cd].[Au] WJCRZORJJRCRAW-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000005242 cardiac chamber Anatomy 0.000 description 1
230000001101 cardioplegic effect Effects 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
229960003115 certolizumab pegol Drugs 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
239000000788 chromium alloy Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
XTYUEDCPRIMJNG-UHFFFAOYSA-N copper zirconium Chemical compound [Cu].[Zr] XTYUEDCPRIMJNG-UHFFFAOYSA-N 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000000850 deacetylating effect Effects 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
229960002923 denileukin diftitox Drugs 0.000 description 1
108010017271 denileukin diftitox Proteins 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
235000004879 dioscorea Nutrition 0.000 description 1
238000002224 dissection Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
229960002224 eculizumab Drugs 0.000 description 1
229960000284 efalizumab Drugs 0.000 description 1
229950009814 efegatran Drugs 0.000 description 1
108010078659 efegatran Proteins 0.000 description 1
239000013536 elastomeric material Substances 0.000 description 1
229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
229950010048 enbucrilate Drugs 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960005167 everolimus Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
238000002594 fluoroscopy Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229910001938 gadolinium oxide Inorganic materials 0.000 description 1
229940075613 gadolinium oxide Drugs 0.000 description 1
CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
RZDQHXVLPYMFLM-UHFFFAOYSA-N gold tantalum Chemical compound [Ta].[Ta].[Ta].[Au] RZDQHXVLPYMFLM-UHFFFAOYSA-N 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
229950010152 halofuginone Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
230000001788 irregular Effects 0.000 description 1
QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960002437 lanreotide Drugs 0.000 description 1
108010021336 lanreotide Proteins 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
238000000608 laser ablation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
108091070501 miRNA Proteins 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
239000003595 mist Substances 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
208000005907 mitral valve insufficiency Diseases 0.000 description 1
208000006887 mitral valve stenosis Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
229960003816 muromonab-cd3 Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
229960005027 natalizumab Drugs 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
SHVHSAYIESIFFO-UHFFFAOYSA-N nickel titanium zirconium Chemical compound [Ti].[Ni].[Zr] SHVHSAYIESIFFO-UHFFFAOYSA-N 0.000 description 1
RJSRQTFBFAJJIL-UHFFFAOYSA-N niobium titanium Chemical compound [Ti].[Nb] RJSRQTFBFAJJIL-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
239000011368 organic material Substances 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229960000402 palivizumab Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
229960001972 panitumumab Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000010702 perfluoropolyether Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920002851 polycationic polymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920002714 polyornithine Polymers 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
229920002620 polyvinyl fluoride Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000003361 porogen Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
210000003102 pulmonary valve Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
210000002321 radial artery Anatomy 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000007342 radical addition reaction Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
108010051412 reteplase Proteins 0.000 description 1
229960002917 reteplase Drugs 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
235000013580 sausages Nutrition 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910001285 shape-memory alloy Inorganic materials 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229910000811 surgical stainless steel Inorganic materials 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229960000216 tenecteplase Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229920001897 terpolymer Polymers 0.000 description 1
238000012360 testing method Methods 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
108010065972 tick anticoagulant peptide Proteins 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
239000003106 tissue adhesive Substances 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
229960005267 tositumomab Drugs 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
229960005342 tranilast Drugs 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
229920000428 triblock copolymer Polymers 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000000591 tricuspid valve Anatomy 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
238000007740 vapor deposition Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000003357 wound healing promoting agent Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/823—Stents, different from stent-grafts, adapted to cover an aneurysm
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0061—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof swellable
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0069—Sealing means
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oral & Maxillofacial Surgery (AREA)
Surgery (AREA)
Transplantation (AREA)
Dispersion Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials Engineering (AREA)
Medicinal Chemistry (AREA)
Prostheses (AREA)
Materials For Medical Uses (AREA)

AU2012307020A 2011-09-09 2012-09-10 Means for controlled sealing of endovascular devices Ceased AU2012307020B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2015205978A AU2015205978B2 (en)	2011-09-09	2015-07-27	Means for controlled sealing of endovascular devices

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201161532814P	2011-09-09	2011-09-09
US61/532,814		2011-09-09
US13/476,695 US9216076B2 (en)	2011-09-09	2012-05-21	Means for controlled sealing of endovascular devices
US13/476,695		2012-05-21
US13/596,894 US20130190857A1 (en)	2011-09-09	2012-08-28	Means for controlled sealing of endovascular devices
US13/596,894		2012-08-28
PCT/AU2012/001080 WO2013033791A1 (fr)	2011-09-09	2012-09-10	Moyens pour l'étanchéification contrôlée de dispositifs endovasculaires

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2015205978A Division AU2015205978B2 (en)	2011-09-09	2015-07-27	Means for controlled sealing of endovascular devices

Publications (2)

Publication Number	Publication Date
AU2012307020A1 AU2012307020A1 (en)	2014-03-13
AU2012307020B2 true AU2012307020B2 (en)	2015-04-30

Family

ID=50237938

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2012307020A Ceased AU2012307020B2 (en)	2011-09-09	2012-09-10	Means for controlled sealing of endovascular devices
AU2015205978A Ceased AU2015205978B2 (en)	2011-09-09	2015-07-27	Means for controlled sealing of endovascular devices

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2015205978A Ceased AU2015205978B2 (en)	2011-09-09	2015-07-27	Means for controlled sealing of endovascular devices

Country Status (8)

Country	Link
EP (1)	EP2753372A4 (fr)
JP (1)	JP6185470B2 (fr)
CN (2)	CN103889472B (fr)
AU (2)	AU2012307020B2 (fr)
BR (1)	BR112014005395A2 (fr)
CA (2)	CA2847687C (fr)
HK (1)	HK1217279A1 (fr)
WO (1)	WO2013033791A1 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005003632A1 (de)	2005-01-20	2006-08-17	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en)	2005-12-22	2007-09-13	Symetis Sa	Stent-valves for valve replacement and associated methods and systems for surgery
US7896915B2 (en)	2007-04-13	2011-03-01	Jenavalve Technology, Inc.	Medical device for treating a heart valve insufficiency
ES2586121T3 (es)	2007-08-21	2016-10-11	Symetis Sa	Válvula de reemplazo
JP5603776B2 (ja)	2007-10-25	2014-10-08	サイメティスエスアー	ステント、弁付きステントおよび方法ならびにその送達システム
US9044318B2 (en)	2008-02-26	2015-06-02	Jenavalve Technology Gmbh	Stent for the positioning and anchoring of a valvular prosthesis
WO2011104269A1 (fr)	2008-02-26	2011-09-01	Jenavalve Technology Inc.	Stent pour le positionnement et l'ancrage d'une prothèse valvulaire dans un site d'implantation dans le cœur d'un patient
US10376359B2 (en)	2009-11-02	2019-08-13	Symetis Sa	Aortic bioprosthesis and systems for delivery thereof
US10856978B2 (en)	2010-05-20	2020-12-08	Jenavalve Technology, Inc.	Catheter system
WO2011147849A1 (fr)	2010-05-25	2011-12-01	Jenavalve Technology Inc.	Valvule prothétique et endoprothèse mise en place par cathétérisme comprenant une valvule prothétique et un stent
US20130274873A1 (en)	2012-03-22	2013-10-17	Symetis Sa	Transcatheter Stent-Valves and Methods, Systems and Devices for Addressing Para-Valve Leakage
US11207176B2 (en)	2012-03-22	2021-12-28	Boston Scientific Scimed, Inc.	Transcatheter stent-valves and methods, systems and devices for addressing para-valve leakage
US20140128964A1 (en)	2012-11-08	2014-05-08	Symetis Sa	Stent Seals and Methods for Sealing an Expandable Stent
US9132007B2 (en)	2013-01-10	2015-09-15	Medtronic CV Luxembourg S.a.r.l.	Anti-paravalvular leakage components for a transcatheter valve prosthesis
US10413401B2 (en) *	2013-02-01	2019-09-17	Medtronic CV Luxembourg S.a.r.l.	Anti-paravalvular leakage component for a transcatheter valve prosthesis
US9675451B2 (en)	2013-02-01	2017-06-13	Medtronic CV Luxembourg S.a.r.l.	Anti-paravalvular leakage component for a transcatheter valve prosthesis
US9155616B2 (en) *	2013-02-28	2015-10-13	St. Jude Medical, Cardiology Division, Inc.	Prosthetic heart valve with expandable microspheres
US9636222B2 (en)	2013-03-12	2017-05-02	St. Jude Medical, Cardiology Division, Inc.	Paravalvular leak protection
US20140350668A1 (en) *	2013-03-13	2014-11-27	Symetis Sa	Prosthesis Seals and Methods for Sealing an Expandable Prosthesis
EP2967862A4 (fr) *	2013-03-15	2017-05-17	Endoluminal Sciences Pty Ltd	Procédé pour l'étanchéité contrôlée de dispositifs endovasculaires
EP3010446B2 (fr)	2013-06-19	2024-03-20	AGA Medical Corporation	Valvule repliable pourvue d'une protection contre les fuites paravalvulaires
EP4098226A1 (fr)	2013-08-30	2022-12-07	JenaValve Technology, Inc.	Endoprothèse comprenant une armature radialement repliable et une valve prothétique
WO2015055652A1 (fr)	2013-10-14	2015-04-23	Symetis Sa	Joint d'étanchéité de prothèse
CN103705315B (zh) *	2013-12-12	2015-10-21	宁波健世生物科技有限公司	防止瓣周漏的主动脉瓣膜支架
EP3125827B1 (fr) *	2014-04-01	2021-09-15	Medtronic CV Luxembourg S.à.r.l.	Composant anti-fuite paravalvulaire pour prothèse de valvule transcathéter
US10195025B2 (en)	2014-05-12	2019-02-05	Edwards Lifesciences Corporation	Prosthetic heart valve
US10213307B2 (en)	2014-11-05	2019-02-26	Medtronic Vascular, Inc.	Transcatheter valve prosthesis having an external skirt for sealing and preventing paravalvular leakage
DE102014223522A1 (de) *	2014-11-18	2016-05-19	Hans-Hinrich Sievers	Biologische Herzklappenprothese
US9693860B2 (en) *	2014-12-01	2017-07-04	Medtronic, Inc.	Segmented transcatheter valve prosthesis having an unsupported valve segment
JP6591554B2 (ja)	2015-02-02	2019-10-16	シメティス・ソシエテ・アノニムＳｙｍｅｔｉｓＳａ	人工心臓弁
US10080652B2 (en) *	2015-03-13	2018-09-25	Boston Scientific Scimed, Inc.	Prosthetic heart valve having an improved tubular seal
EP3270825B1 (fr)	2015-03-20	2020-04-22	JenaValve Technology, Inc.	Système de pose de prothèse de valvule cardiaque
WO2016177562A1 (fr)	2015-05-01	2016-11-10	Jenavalve Technology, Inc.	Dispositif et procédé à débit réduit de stimulateur cardiaque lors d'un remplacement de valvules cardiaques
US20170056164A1 (en) *	2015-09-02	2017-03-02	Medtronic Vascular, Inc.	Transcatheter valve prostheses having a sealing component formed from tissue having an altered extracellular matrix
CN105326581B (zh) *	2015-09-29	2017-12-26	中国科学院金属研究所	一种制备聚乙二醇‑蛋白质纤维复合人工心脏瓣膜的方法
WO2017121803A1 (fr) *	2016-01-14	2017-07-20	Cardiatis S.A.	Prothèse implantable pour maladie aortique thoracique impliquant un dysfonctionnement valvulaire aortique
US10179043B2 (en) *	2016-02-12	2019-01-15	Edwards Lifesciences Corporation	Prosthetic heart valve having multi-level sealing member
US20200121454A1 (en) *	2016-03-01	2020-04-23	Paul A. Spence	System, devices and methods for anchoring and/or sealing a heart valve prosthesis
EP3429509B1 (fr)	2016-03-14	2024-10-16	Medtronic Vascular Inc.	Valvule cardiaque prosthétique à endoprothèse présentant une enveloppe et des dispositifs d'administration
EP4183371A1 (fr)	2016-05-13	2023-05-24	JenaValve Technology, Inc.	Système de pose de prothèse de valvule cardiaque et procédé de pose de prothèse de valvule cardiaque avec gaine d'introduction et système de chargement
WO2017201082A1 (fr) *	2016-05-17	2017-11-23	Nsvascular, Inc.	Valvule cardiaque transcathéter en couche mince
CN109475402A (zh) *	2016-06-21	2019-03-15	美敦力瓦斯科尔勒公司	用于动脉瘤治疗的涂覆的血管内假体
JP2018027155A (ja) *	2016-08-16	2018-02-22	安彦杉本	ステント
CN106214287A (zh) *	2016-08-24	2016-12-14	杨威	主动脉夹层手术用覆膜支架、输送装置以及使用方法
CN106420126A (zh) *	2016-10-31	2017-02-22	中山大学附属第医院	血管支架
US10813749B2 (en)	2016-12-20	2020-10-27	Edwards Lifesciences Corporation	Docking device made with 3D woven fabric
JP7094965B2 (ja)	2017-01-27	2022-07-04	イエナバルブテクノロジーインク	心臓弁模倣
CN106957397A (zh) *	2017-02-27	2017-07-18	杭州启明医疗器械有限公司	防周漏水凝胶材料及其制备方法
US11284984B2 (en)	2017-05-02	2022-03-29	Medtronic Vascular, Inc.	Assemblies and methods of sterilizing a wet stored prosthetic heart valve
WO2018204445A1 (fr)	2017-05-02	2018-11-08	Medtronic Vascular Inc.	Emballage pour valvule cardiaque prothétique à l'état de tissu sec
IL309520B1 (en) *	2017-05-31	2025-10-01	Edwards Lifesciences Corp	Sealing component for heart valve bushing
CN107411849B (zh) *	2017-08-24	2018-11-30	北京航空航天大学	防瓣周漏经导管瓣膜系统及植入方法
CN109431652A (zh) *	2017-09-04	2019-03-08	杭州启明医疗器械股份有限公司	一种便于装载的防周漏支架装置及加工方法、裙边褶皱方法、心脏瓣膜
CN109567891A (zh) *	2017-09-29	2019-04-05	上海微创医疗器械（集团）有限公司	左心耳封堵器及左心耳封堵装置
CN120770981A (zh) *	2017-10-30	2025-10-14	安多拉米诺科学公司	用于防渗漏血管内假体的可扩张密封裙部技术
JP7237997B2 (ja) *	2018-03-27	2023-03-13	マドゥロディスカバリー，エルエルシ―	インターベンション治療中の神経保護のための付属装置
CN110313946A (zh) *	2018-03-28	2019-10-11	上海微创医疗器械（集团）有限公司	一种封堵装置及其制备方法
WO2019195860A2 (fr)	2018-04-04	2019-10-10	Vdyne, Llc	Dispositifs et procédés d'ancrage d'une valvule cardiaque transcathéter
US11344413B2 (en)	2018-09-20	2022-05-31	Vdyne, Inc.	Transcatheter deliverable prosthetic heart valves and methods of delivery
US12186187B2 (en)	2018-09-20	2025-01-07	Vdyne, Inc.	Transcatheter deliverable prosthetic heart valves and methods of delivery
US10321995B1 (en)	2018-09-20	2019-06-18	Vdyne, Llc	Orthogonally delivered transcatheter heart valve replacement
US11278437B2 (en)	2018-12-08	2022-03-22	Vdyne, Inc.	Compression capable annular frames for side delivery of transcatheter heart valve replacement
US10595994B1 (en)	2018-09-20	2020-03-24	Vdyne, Llc	Side-delivered transcatheter heart valve replacement
US11071627B2 (en)	2018-10-18	2021-07-27	Vdyne, Inc.	Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis
US11109969B2 (en)	2018-10-22	2021-09-07	Vdyne, Inc.	Guidewire delivery of transcatheter heart valve
US11253359B2 (en)	2018-12-20	2022-02-22	Vdyne, Inc.	Proximal tab for side-delivered transcatheter heart valves and methods of delivery
CN109481085A (zh) *	2018-12-25	2019-03-19	天津市胸科医院	一种施加有药物的介入瓣膜
WO2020146842A1 (fr)	2019-01-10	2020-07-16	Vdyne, Llc	Crochet d'ancrage pour prothèse de valvule cardiaque transcathéter à distribution latérale
US11273032B2 (en)	2019-01-26	2022-03-15	Vdyne, Inc.	Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis
US11185409B2 (en)	2019-01-26	2021-11-30	Vdyne, Inc.	Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis
CN113557042A (zh) *	2019-02-19	2021-10-26	Tc1有限责任公司	人工血管和用于密封人工血管的方法
US11278402B2 (en)	2019-02-21	2022-03-22	Medtronic, Inc.	Prosthesis for transcatheter delivery having an infolding longitudinal segment for a smaller radially compressed profile
CN120899433A (zh)	2019-03-05	2025-11-07	维迪内股份有限公司	用于正交经导管心脏瓣膜假体的三尖瓣反流控制装置
US11076956B2 (en)	2019-03-14	2021-08-03	Vdyne, Inc.	Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis
US11173027B2 (en)	2019-03-14	2021-11-16	Vdyne, Inc.	Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
CN120827457A (zh)	2019-05-04	2025-10-24	维迪内股份有限公司	用于在自体瓣环中部署侧面递送的假体心脏瓣膜的束紧装置和方法
CA3152042A1 (fr)	2019-08-20	2021-02-25	Vdyne, Inc.	Dispositifs d'administration et de recuperation et procedes pour valvules prothetiques transcatheter a pose laterale
AU2020337235A1 (en)	2019-08-26	2022-03-24	Vdyne, Inc.	Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
EP3786132A1 (fr) *	2019-08-29	2021-03-03	Sika Technology AG	Matériaux d'injection à base acrylique présentant de meilleures propriétés de durcissement
CN110478085B (zh) *	2019-09-12	2022-05-17	成都赛拉诺医疗科技有限公司	心脏瓣膜假体及其可填充结构
US11583397B2 (en)	2019-09-24	2023-02-21	Medtronic, Inc.	Prosthesis with anti-paravalvular leakage component including a one-way valve
JP7518159B2 (ja) *	2019-10-02	2024-07-17	フィリップ・モーリス・プロダクツ・ソシエテ・アノニム	エアロゾル発生装置用の、形状記憶材料から形成されたサセプタ発熱体
WO2021073978A1 (fr) *	2019-10-17	2021-04-22	Cortronik GmbH	Matériau d'étanchéité pour implant médical
CN111157603A (zh) *	2019-12-23	2020-05-15	杭州师范大学	聚丙烯酰胺凝胶制板少量分离胶快凝防漏方法
US20210212727A1 (en) *	2020-01-10	2021-07-15	Csaba Truckai	Medical device and method for preventing adhesions
US11234813B2 (en)	2020-01-17	2022-02-01	Vdyne, Inc.	Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery
WO2024102411A1 (fr)	2022-11-09	2024-05-16	Jenavalve Technology, Inc.	Système de cathéter pour le déploiement séquentiel d'un implant expansible
CN117481873B (zh) *	2024-01-02	2024-04-26	杭州启明医疗器械股份有限公司	人工植入物以及介入系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6271278B1 (en) *	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US20030232895A1 (en) *	2002-04-22	2003-12-18	Hossein Omidian	Hydrogels having enhanced elasticity and mechanical strength properties

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5554185A (en) *	1994-07-18	1996-09-10	Block; Peter C.	Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same
US5769882A (en) *	1995-09-08	1998-06-23	Medtronic, Inc.	Methods and apparatus for conformably sealing prostheses within body lumens
US6878161B2 (en) *	1996-01-05	2005-04-12	Medtronic Vascular, Inc.	Stent graft loading and deployment device and method
US6398758B1 (en) *	1999-02-16	2002-06-04	Stephen C. Jacobsen	Medicament delivery system
RU2311892C2 (ru) *	2001-08-29	2007-12-10	КАРВАЛХО Рикардо А. П. ДЕ	Имплантируемая и герметизируемая система для однонаправленной доставки терапевтических препаратов в ткани
US7105021B2 (en) *	2002-04-25	2006-09-12	Scimed Life Systems, Inc.	Implantable textile prostheses having PTFE cold drawn yarns
US20030204249A1 (en) *	2002-04-25	2003-10-30	Michel Letort	Endovascular stent graft and fixation cuff
US20040260382A1 (en) *	2003-02-12	2004-12-23	Fogarty Thomas J.	Intravascular implants and methods of using the same
US7780725B2 (en) *	2004-06-16	2010-08-24	Sadra Medical, Inc.	Everting heart valve
US7445630B2 (en) *	2004-05-05	2008-11-04	Direct Flow Medical, Inc.	Method of in situ formation of translumenally deployable heart valve support
US20070179600A1 (en) *	2004-10-04	2007-08-02	Gil Vardi	Stent graft including expandable cuff
US7955372B2 (en) *	2005-06-01	2011-06-07	Board Of Trustees Of The Leland Stanford Junior University	Endoluminal delivery system
US20070244544A1 (en) *	2006-04-14	2007-10-18	Medtronic Vascular, Inc.	Seal for Enhanced Stented Valve Fixation
GB0616738D0 (en) *	2006-08-23	2006-10-04	Evexar Medical Ltd	Improvements in and relating to medical devices
US7578842B2 (en) *	2006-10-03	2009-08-25	St. Jude Medical, Inc.	Prosthetic heart valves
US9848981B2 (en) *	2007-10-12	2017-12-26	Mayo Foundation For Medical Education And Research	Expandable valve prosthesis with sealing mechanism
WO2010083558A1 (fr) *	2009-01-23	2010-07-29	Endoluminal Sciences Pty Ltd	Dispositifs endovasculaires, systèmes et procédés associés

2012
- 2012-09-10 AU AU2012307020A patent/AU2012307020B2/en not_active Ceased
- 2012-09-10 CA CA2847687A patent/CA2847687C/fr not_active Expired - Fee Related
- 2012-09-10 CA CA2952464A patent/CA2952464A1/fr not_active Abandoned
- 2012-09-10 BR BR112014005395A patent/BR112014005395A2/pt not_active IP Right Cessation
- 2012-09-10 JP JP2014528801A patent/JP6185470B2/ja not_active Expired - Fee Related
- 2012-09-10 CN CN201280043199.5A patent/CN103889472B/zh not_active Expired - Fee Related
- 2012-09-10 CN CN201510526959.3A patent/CN105232187A/zh active Pending
- 2012-09-10 WO PCT/AU2012/001080 patent/WO2013033791A1/fr not_active Ceased
- 2012-09-10 EP EP12829481.6A patent/EP2753372A4/fr not_active Withdrawn
2015
- 2015-07-27 AU AU2015205978A patent/AU2015205978B2/en not_active Ceased
2016
- 2016-05-09 HK HK16105252.4A patent/HK1217279A1/zh unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6271278B1 (en) *	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US20030232895A1 (en) *	2002-04-22	2003-12-18	Hossein Omidian	Hydrogels having enhanced elasticity and mechanical strength properties

Also Published As

Publication number	Publication date
CN103889472A (zh)	2014-06-25
HK1217279A1 (zh)	2017-01-06
AU2015205978A1 (en)	2015-08-20
BR112014005395A2 (pt)	2017-03-28
JP6185470B2 (ja)	2017-08-23
JP2014529475A (ja)	2014-11-13
AU2015205978B2 (en)	2017-04-06
WO2013033791A1 (fr)	2013-03-14
EP2753372A1 (fr)	2014-07-16
EP2753372A4 (fr)	2015-08-05
CN103889472B (zh)	2016-08-24
CA2847687A1 (fr)	2013-03-14
CA2952464A1 (fr)	2013-03-14
AU2012307020A1 (en)	2014-03-13
CN105232187A (zh)	2016-01-13
CA2847687C (fr)	2017-10-17

Publication	Publication Date	Title
AU2012307020B2 (en)	2015-04-30	Means for controlled sealing of endovascular devices
US20190374326A1 (en)	2019-12-12	Means for controlled sealing of endovascular devices
US9216076B2 (en)	2015-12-22	Means for controlled sealing of endovascular devices
US20160030165A1 (en)	2016-02-04	Means for Controlled Sealing of Endovascular Devices
US20130331929A1 (en)	2013-12-12	Means for Controlled Sealing of Endovascular Devices
US20160194425A1 (en)	2016-07-07	Highly expandable hydrogels in medical device sealing technology
US7955372B2 (en)	2011-06-07	Endoluminal delivery system
JP6392778B2 (ja)	2018-09-19	人工心臓弁リーフレットにおける曲げ特性の幾何学的制御
US20100204775A1 (en)	2010-08-12	Tissue Synthetic- Biomaterial Hybrid Medical Devices
US20170119362A1 (en)	2017-05-04	Device and Method for Closure of Atrial Septal Defects
RS64665B1 (sr)	2023-11-30	Zaptivena tkanina za upotrebu kao medicinski materijal
WO2004112863A1 (fr)	2004-12-29	Implant recouvert d'une membrane biodegradable comportant du chitosane
CN109640883A (zh)	2019-04-16	减少支架移植物内漏的带涂层缝合线
Cohn et al.	2019	In situ generated medical devices
CN103249375A (zh)	2013-08-14	抗沾粘外科入路、加固性与封闭假体
CN106937895B (zh)	2020-12-18	覆膜支架及其制备方法
ES2746804T3 (es)	2020-03-06	Composiciones para la reparación de tejidos de los vasos sanguíneos
WO2023211924A1 (fr)	2023-11-02	Procédés, systèmes et dispositifs pour l'occlusion de l'appendice auriculaire gauche
US20230210539A1 (en)	2023-07-06	Elastin formation using fibrous implants
WO2016075691A1 (fr)	2016-05-19	Dispositifs biomédicaux prêts à l'emploi pour soudage in vivo
CN116583309A (zh)	2023-08-11	脱细胞组织/聚合物多组分生物材料
KR20140096772A (ko)	2014-08-06	접착성 물질을 이용하여 신체 이식 후 이동을 최소화하는 스텐트 및 방법
HK1153158A (en)	2012-03-23	Device for closure of atrial septal defects

Legal Events

Date	Code	Title	Description
2015-08-27	FGA	Letters patent sealed or granted (standard patent)
2018-04-05	MK14	Patent ceased section 143(a) (annual fees not paid) or expired